Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 14Not yet recruiting 6Active not recruiting 6Terminated 3Withdrawn 1Enrolling by invitation 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 28Neoplasms 26Prostatic Neoplasms 22Colorectal Neoplasms 18Head and Neck Neoplasms 14Pancreatic Neoplasms 12Melanoma 10Lung Neoplasms 10Brain Neoplasms 10Neoplasm Metastasis 9Carcinoma, Renal Cell 9Squamous Cell Carcinoma of Head and Neck 8Carcinoma, Non-Small-Cell Lung 8Triple Negative Breast Neoplasms 7Recurrence 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Multiple Myeloma 7Lymphoma, Follicular 7Lymphoma 7Glioblastoma 7Leukemia, Myeloid, Acute 6Leukemia 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 5Ovarian Neoplasms 5Lymphoma, B-Cell 5Kidney Neoplasms 5Hematologic Neoplasms 5Sarcoma 4Liver Neoplasms 4

Interventions

pembrolizumab 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Clear-cell metastatic renal cell carcinoma × 1 year × Clear all
NCT06361810 2025-08-19

PSMA Therapy and Immunotherapy in Kidney Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Withdrawn
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡